Skip to main content
Erschienen in: Clinical Rheumatology 4/2018

22.02.2018 | Original Article

Ischemic heart disease and ankylosing spondylitis—assessing the role of inflammation

verfasst von: Michal Vinker Shuster, Omer Gendelman, Shmuel Tiosano, Doron Comaneshter, Arnon D. Cohen, Howard Amital

Erschienen in: Clinical Rheumatology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

To assess the association of ankylosing spondylitis (AS) and ischemic heart disease (IHD) compared to traditional cardiovascular (CV) risk factors. Primary care and hospital records of patients with AS were analyzed, using the largest health maintenance organization in Israel, the “Clalit” Health Services data. These patients were compared with age- and gender-matched controls regarding the proportion of IHD in a cross-sectional study. Parameters including socioeconomic status, body mass index (BMI), smoking habits, and coexistent medical conditions hypertension, hyperlipidemia, and diabetes mellitus (DM) - as well as the use of NSAIDs and anti-TNFs were also assessed. The study included 4076 AS patients compared to 20,290 age- and gender-matched controls without AS. The proportion of IHD was higher among AS patients as compared to controls (14.1 vs. 6.36%, respectively, p < 0.01) and patients treated with anti-TNFs had a lower risk for IHD compared to non-anti-TNF users. The proportion of hypertension, hyperlipidemia, DM, and smoking was also higher among AS patients. However, in multivariate analyses following adjustment to these risk factors, AS was not found to be associated with IHD nor anti-TNF therapy to be a protective factor. Patients with AS have more traditional CV risk factors, thus are in a higher risk for IHD. AS itself was not shown to be independently associated with IHD. These findings emphasize the multifactorial process leading to increased proportion of IHD among AS patients and the need for a stringent control of traditional risk factors in these patients.
Literatur
2.
Zurück zum Zitat El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22(6):554–560CrossRefPubMed El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22(6):554–560CrossRefPubMed
3.
Zurück zum Zitat Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology 53(4):650–657CrossRefPubMed Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ (2014) Global prevalence of ankylosing spondylitis. Rheumatology 53(4):650–657CrossRefPubMed
6.
Zurück zum Zitat Momeni M, Taylor N, Tehrani M (2011) Cardiopulmonary manifestations of ankylosing spondylitis. Int J Rheumatol 2011:1–6CrossRef Momeni M, Taylor N, Tehrani M (2011) Cardiopulmonary manifestations of ankylosing spondylitis. Int J Rheumatol 2011:1–6CrossRef
8.
Zurück zum Zitat Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed Han C, Robinson DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed
12.
Zurück zum Zitat Mathieu S, Motreff P, Soubrier M (2010) Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 77(6):542–545CrossRefPubMed Mathieu S, Motreff P, Soubrier M (2010) Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 77(6):542–545CrossRefPubMed
13.
Zurück zum Zitat Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26(5):710–714CrossRefPubMed Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G (2007) High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 26(5):710–714CrossRefPubMed
14.
Zurück zum Zitat Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 109(2):171–176CrossRefPubMed Divecha H, Sattar N, Rumley A, Cherry L, Lowe GDO, Sturrock R (2005) Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 109(2):171–176CrossRefPubMed
15.
Zurück zum Zitat Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592 Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592
16.
Zurück zum Zitat Murray CJL, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369(5):448–457CrossRefPubMed Murray CJL, Lopez AD (2013) Measuring the global burden of disease. N Engl J Med 369(5):448–457CrossRefPubMed
17.
25.
Zurück zum Zitat Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347CrossRefPubMed Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347CrossRefPubMed
26.
Zurück zum Zitat Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2):69–75CrossRefPubMed Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2):69–75CrossRefPubMed
27.
Zurück zum Zitat Del Rincón I, Williams K, Stern MP, Freeman GL, O’leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840CrossRefPubMed Del Rincón I, Williams K, Stern MP, Freeman GL, O’leary DH, Escalante A (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48(7):1833–1840CrossRefPubMed
28.
Zurück zum Zitat Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406CrossRefPubMed Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406CrossRefPubMed
29.
30.
Zurück zum Zitat Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M, Onen F, Akkoc N (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45(3):283–286CrossRefPubMed Sari I, Okan T, Akar S, Cece H, Altay C, Secil M, Birlik M, Onen F, Akkoc N (2006) Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45(3):283–286CrossRefPubMed
31.
Zurück zum Zitat Peters MJL, Smulders Y, Serne E, Dijkmans B, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166CrossRefPubMed Peters MJL, Smulders Y, Serne E, Dijkmans B, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166CrossRefPubMed
32.
Zurück zum Zitat Van Eijk IC, Peters MJL, Serne EH et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis 68(3):362–366CrossRefPubMed Van Eijk IC, Peters MJL, Serne EH et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor α blockade. Ann Rheum Dis 68(3):362–366CrossRefPubMed
33.
Zurück zum Zitat Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489. https://doi.org/10.1136/annrheumdis-2014-206624 CrossRefPubMedPubMedCentral Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489. https://​doi.​org/​10.​1136/​annrheumdis-2014-206624 CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Clegg DO (2006) Treatment of ankylosing spondylitis. J Rheumatol Suppl 33(78):24 Clegg DO (2006) Treatment of ankylosing spondylitis. J Rheumatol Suppl 33(78):24
35.
Zurück zum Zitat Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563–2574CrossRefPubMed Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563–2574CrossRefPubMed
36.
Zurück zum Zitat McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8(9):e1001098CrossRefPubMedPubMedCentral McGettigan P, Henry D (2011) Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 8(9):e1001098CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Bolten WW (2006) Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65(1):7–13CrossRefPubMed Bolten WW (2006) Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis 65(1):7–13CrossRefPubMed
38.
Zurück zum Zitat Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331CrossRefPubMed Peters MJL, Symmons DPM, McCarey D, Dijkmans BAC, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331CrossRefPubMed
39.
Zurück zum Zitat Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI (2012) Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 14(3):R141CrossRefPubMedPubMedCentral Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, Kardassis D, Boumpas DT, Sidiropoulos PI (2012) Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 14(3):R141CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Daïen CI, Duny Y, Barnetche T, Daurès J-P, Combe B, Morel J (2012) Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71(6):862–868CrossRefPubMed Daïen CI, Duny Y, Barnetche T, Daurès J-P, Combe B, Morel J (2012) Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71(6):862–868CrossRefPubMed
41.
Zurück zum Zitat Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, Ostor AJK, Edwards CJ (2011) Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 50(3):518–531CrossRefPubMed Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, Choy E, Ostor AJK, Edwards CJ (2011) Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 50(3):518–531CrossRefPubMed
42.
Zurück zum Zitat Barnabe C, Martin B, Ghali WA (2011) Systematic review and meta-analysis: anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63(4):522–529CrossRef Barnabe C, Martin B, Ghali WA (2011) Systematic review and meta-analysis: anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 63(4):522–529CrossRef
Metadaten
Titel
Ischemic heart disease and ankylosing spondylitis—assessing the role of inflammation
verfasst von
Michal Vinker Shuster
Omer Gendelman
Shmuel Tiosano
Doron Comaneshter
Arnon D. Cohen
Howard Amital
Publikationsdatum
22.02.2018
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 4/2018
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4037-y

Weitere Artikel der Ausgabe 4/2018

Clinical Rheumatology 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.